Advances have been made in the field of nonalcoholic fatty liver disease in 2019. One paper highlights the role of gut microbiota in hepatocellular carcinoma (HCC) pathogenesis, another presents a noninvasive algorithm for detecting advanced liver fibrosis and another suggests a potential novel approach to treating nonalcoholic steatohepatitis and suppressing HCC development.
Key advances
The altered gut microbiota profile is associated with systemic inflammation in patients with nonalcoholic fatty liver disease (NAFLD)-related cirrhosis who have hepatocellular carcinoma2
Measuring blood markers related to type III collagen might be useful for staging liver fibrosis in both adults and children with NAFLD5,6
Platelet count, activation and aggregation are increased in nonalcoholic steatohepatitis (NASH) and antiplatelet therapies should be tested10
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway
Molecular Biology Reports Open Access 14 November 2022
-
MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis
Molecular Biomedicine Open Access 10 August 2022
-
Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis
Lipids in Health and Disease Open Access 02 March 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sanyal, A. J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 16, 377–386 (2019).
Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107–120 (2019).
Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504–516 (2012).
Byrne, C. D. et al. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ 362, k2734 (2018).
Daniels, S. J. et al. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 69, 1075–1086 (2019).
Mosca, A. et al. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. Liver Int. https://doi.org/10.1111/liv.14225 (2019).
Iannacone, M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1167–1169 (2005).
Sitia, G. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl Acad. Sci. USA 109, E2165–E2172 (2012).
Pavlovic, N. et al. Platelets as key factors in hepatocellular carcinoma. Cancers 11, E1022 (2019).
Malehmir, M. et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 25, 641–655 (2019).
Acknowledgements
C.D.B. is supported in part by Southampton National Institute for Health Research Biomedical Research Centre, UK. G.T. is supported in part by the University School of Medicine of Verona, Italy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Byrne, C.D., Targher, G. What’s new in NAFLD pathogenesis, biomarkers and treatment?. Nat Rev Gastroenterol Hepatol 17, 70–71 (2020). https://doi.org/10.1038/s41575-019-0239-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0239-2
This article is cited by
-
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Nature Reviews Endocrinology (2024)
-
HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway
Molecular Biology Reports (2023)
-
MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis
Molecular Biomedicine (2022)
-
Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis
Lipids in Health and Disease (2022)
-
Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice
Nature Communications (2022)